SAA与前列腺癌病理分级和临床分期的关系

目的评估前列腺癌患者血清淀粉样蛋白A(serum amyloid A,SAA)在前列腺癌不同病理分化和临床分期中表达的差异。方法纳入前列腺癌患者48例,前列腺增生患者32例,测定SAA水平,并将前列腺癌患者的SAA水平与肿瘤病理分化和临床分期结果进行对比分析。结果前列腺癌和良性前列腺增生患者的SAA水平的差异有统计学意义(P<0.01),随着肿瘤分化的降低和分期的增加,SAA水平逐渐增高。结论 SAA在前列腺癌患者中的表达明显增高,可作为前列腺癌分化、分期和预后评估的重要指标。

Objective To evaluate the relationship between serum amyloid A protein（SAA）and tumor pathological grading and clinical staging in prostate cancer.Methods The levels of SAA were measured in 48 patients with prostate cancer and 32 patients with prostate hyperplasia.The relationship between SAA levels and tumor grading and staging were also analyzed.Results There was significant difference of SAA levels between prostate cancer and prostate hyperplasia（P0.01）.The SAA levels increased as the tumor pathological grading decreased and the clinical staging increased.Conclusion The SAA levels increased significantly in prostate cancer patients,and could be applied as the biomarker of prostate cancer pathological grading,clinical staging and prognosis.